IP Library › Granted Patent US 11,065,308
Granted Patent B2
US 11,065,308 · App. 16/036,584 · Granted Jul 20, 2021

Methods and compositions for CNS delivery of heparan n-sulfatase

Inventors: Farah Natoli (Georgetown, MA); Gaozhong Zhu (Weston, MA); Jennifer Terew (Concord, MA); Yuan Jiang (Londonderry, NH); Jamie Tsung (Wellesley, MA); Zahra Shahrokh (Weston, MA); Brian Vernaglia (Winchester, MA); Jing Pan (Boxborough, MA); Richard Pfeifer (North Granby, CT); Pericles Calias (Melrose, MA)
Assignee: Shire Human Genetic Therapies, Inc.
A61K38/47A61K9/0019A61K9/0085A61K9/08A61K9/19A61K35/76A61K35/761A61K38/46A61K38/465A61K47/02A61K47/26C07K14/65C12N9/2402C12N9/2437C12Y301/06008C12Y301/06013C12Y302/0105C12Y302/01045C12Y302/01046C12Y310/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,308
App. No.
16/036,584
Granted
Jul 20, 2021
Kind
B2
Abstract

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

Claims (6)

1. A method of treating Sanfilippo A Syndrome comprising a step of

administering intrathecally to a subject in need of treatment a formulation comprising a heparan N-sulfatase (HNS) protein at a concentration at or greater than 5 mg/ml, and no greater than 50 mM phosphate.

2. The method of claim 1 , wherein the intrathecal administration of the formulation results in reduction of lysosomal storage in the brain target tissues, spinal cord neurons and peripheral target tissues.

3. The method of claim 1 , wherein the intrathecal administration of the formulation results in reduced intensity, severity, or frequency, or delayed onset of at least one symptom or feature of the Sanfilippo A Syndrome.

4. The method of claim 1 , wherein the intrathecal administration is used in conjunction with intravenous administration.

5. The method of claim 1 , wherein the intrathecal administration is used in absence of concurrent immunosuppressive therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061447/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: NATOLI, FARAH; ZHU, GAOZHONG; TEREW, JENNIFER; JIANG, YUAN; TSUNG, JAMIE; SHAHROKH, ZAHRA; VERNAGLIA, BRIAN; PAN, JING; PFEIFER, RICHARD; CALIAS, PERICLES
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 048741/0616 →
Continuity (10)
Continuation 15077046 · Mar 22, 2016
Division 13168957 · Jun 25, 2011
Provisional Application 61495268 · Jun 9, 2011
Provisional Application 61476210 · Apr 15, 2011
Provisional Application 61442115 · Feb 11, 2011
Provisional Application 61435710 · Jan 24, 2011
Provisional Application 61387862 · Sep 29, 2010
Provisional Application 61360786 · Jul 1, 2010
Provisional Application 61358857 · Jun 25, 2010
Related Publication 20190183984A1 · Jun 20, 2019
Cited By (1)
US 12,409,210